Skip to main content
Premium Trial:

Request an Annual Quote

Sorrento Therapeutics Licenses Saliva-Based Coronavirus Test From Columbia University

NEW YORK — Drug developer Sorrento Therapeutics said on Wednesday that it has licensed a rapid point-of-care SARS-CoV-2 test from Columbia University.

According to the San Diego-based company, the reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based test involves placing a saliva or nasopharyngeal swab sample into a tube that is warmed in a heat block or water bath. A colorimetric readout is provided within 30 minutes, confirming the presence or absence of viral RNA.

The test, which will be marketed by Sorrento under the Covi-Trace brand name, was developed by Columbia University Fertility Center's Zev Williams based on technology he and his team used for preimplantation genetic testing. As reported in a preprint last month, the test has demonstrated 97 percent sensitivity and 100 percent specificity. 

"We are building a portfolio of highly relevant COVID-19 solutions that spans diagnostics, prevention, early intervention, and rescue therapies," Sorrento Chairman and CEO Henry Ji said in a statement. "Covi-Trace will be a key asset in our diagnostic solutions, and we intend to move rapidly to submit an emergency use authorization request to the FDA and prepare for full-scale production."

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.